Logo (EUIPO, 12/30/2022)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark was filed as Figurative mark on 12/30/2022 at the European Union Intellectual Property Office.
It was registered as a trademark on 05/30/2023.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Luminous sources, rays, shafts of light #Waves, sound and micro waves. #Lighthouses #One circle #Circles with dark surfaces or parts of surfaces
| Trademark form | Figurative mark |
| File reference | 018816857 |
| Application date | December 30, 2022 |
| Publication date | February 20, 2023 |
| Entry date | May 30, 2023 |
| Expiration date | December 30, 2032 |
Trademark owner
10578 Science Drive, Suite 125
92121 San Diego
US
92121 San Diego
US
Trademark representatives
Arne Jacobsens Allé 15
2300 Copenhagen S
DK
goods and services
5
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological, medicinal and pharmaceutical preparations for medical purposes; biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; diagnostic preparations, namely for sample preparation, modification and manipulation of cells as well as for labelling, separation, isolation, purification, amplification and/or analysis of natural or synthetic biopolymers, namely nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances; oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; oligonucleotide compounds for use in targeted gene silencing; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies; reagents, oligonucleotides, antibodies, in-vitro diagnostics and control reagents for medical purposes, being kit components; kits, containing primarily of reagents, oligonucleotides, antibodies, in-vitro diagnostic preparations, control reagents, electronic or online manuals and/or instruments for biochemical, molecular biological and immunological testing
42
Conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, namely, conducting clinical trials for oligonucleotide-based therapeutics; conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; consultancy relating to pharmaceutical research and development; development of pharmaceutical preparations and medicines; services for assessing the efficiency of pharmaceuticals; testing of pharmaceuticals; providing information about the results of clinical trials for pharmaceutical products; scientific research for medical purposes; pharmaceutical product evaluation; medical research laboratory services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development in the pharmaceutical and biotechnology fields; research and development in the pharmaceutical and biotechnology fields, namely, research and development for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; research and development in the pharmaceutical and biotechnology fields, namely, research and development for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development for the use of antibody-oligonucleotide conjugates for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and scientific research services for the use of antibody-oligonucleotide conjugates for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; medical and scientific research services for the use of antibody-oligonucleotide conjugates for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; development of pharmaceutical preparations and medicines, namely, the development of oligonucleotide-based therapeutics; scientific research and development; scientific investigations for medical purposes; research and development of oligonucleotide drug delivery platforms for use in the treatment of genetic diseases and disorders; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; research and development of oligonucleotide compounds for targeted gene silencing
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 29, 2024 | Change Representative, Published |
ID: 11018816857